Online inquiry

IVTScrip™ mRNA-Anti-IL17RA, AMG827(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ2901MR)

This product GTTS-WQ2901MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets IL17RA gene. The antibody can be applied in Crohn's disease (CD) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001289905.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 23765
UniProt ID Q96F46
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL17RA, AMG827(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ2901MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9600MR IVTScrip™ mRNA-Anti-VSIR, JNJ-61610588(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA JNJ-61610588
GTTS-WQ6211MR IVTScrip™ mRNA-Anti-RABVgp4, CR4098(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA CR4098
GTTS-WQ3992MR IVTScrip™ mRNA-Anti-LTB&TNFSF14, BG9924(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BG9924
GTTS-WQ13012MR IVTScrip™ mRNA-Anti-CSF3R, PEG-G-CSF(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA PEG-G-CSF
GTTS-WQ4530MR IVTScrip™ mRNA-Anti-PDCD1, BMS-936558(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-936558
GTTS-WQ1140MR IVTScrip™ mRNA-Anti-VEGFA, ABP 215(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ABP 215
GTTS-WQ3474MR IVTScrip™ mRNA-Anti-pcrV, BA1126(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BA1126
GTTS-WQ7387MR IVTScrip™ mRNA-Anti-MS4A1, GA101(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA GA101
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW